Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.49 -6.3%	$1.50	$1.03 ▼ $8.64	$46.48M	-0.27	505,432 shs	489,218 shs
DBVT DBV Technologies	$9.10 -6.1%	$8.89	$2.20 ▼ $12.78	$249.25M	-0.63	190,009 shs	13,611 shs
ESPR Esperion Therapeutics	$1.17 -2.5%	$0.95	$0.69 ▼ $3.94	$231.89M	0.67	5.28 million shs	2.15 million shs
MDWD MediWound	$20.42 +0.3%	$18.97	$12.78 ▼ $24.00	$220.70M	0.38	91,980 shs	27,940 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	-6.29%	-18.58%	+2.05%	+21.14%	-81.72%
DBVT DBV Technologies	-6.09%	-0.33%	-20.73%	+86.86%	+73.33%
ESPR Esperion Therapeutics	-2.50%	-4.10%	+60.27%	-22.00%	-59.52%
MDWD MediWound	+0.34%	-5.46%	+5.10%	+10.14%	+26.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATNM Actinium Pharmaceuticals	1.1903 of 5 stars	3.4	2.0	0.0	0.0	0.0	0.6
DBVT DBV Technologies	3.3555 of 5 stars	3.3	5.0	0.0	3.0	2.5	0.6
ESPR Esperion Therapeutics	4.0465 of 5 stars	3.3	3.0	3.9	2.7	1.7	0.6
MDWD MediWound	2.0505 of 5 stars	3.5	1.0	0.0	3.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNM Actinium Pharmaceuticals	2.75	Moderate Buy	$4.00	168.46% Upside
DBVT DBV Technologies	2.50	Moderate Buy	$14.75	62.09% Upside
ESPR Esperion Therapeutics	2.50	Moderate Buy	$6.25	434.19% Upside
MDWD MediWound	3.00	Buy	$31.80	55.73% Upside

Current Analyst Ratings Breakdown

Latest ATNM, ESPR, DBVT, and MDWD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$34.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/22/2025	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00 ➝ $31.00
5/12/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
5/5/2025	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $16.00
5/2/2025	MDWD MediWound	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
5/1/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $15.00
4/28/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNM Actinium Pharmaceuticals	$81K	573.85	N/A	N/A	$1.31 per share	1.14
DBVT DBV Technologies	$15.73M	15.85	N/A	N/A	$7.27 per share	1.25
ESPR Esperion Therapeutics	$259.57M	0.89	N/A	N/A	($3.85) per share	-0.30
MDWD MediWound	$19.21M	11.49	N/A	N/A	$3.43 per share	5.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNM Actinium Pharmaceuticals	-$48.82M	-$1.39	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
DBVT DBV Technologies	-$72.73M	-$4.92	N/A	N/A	N/A	-815.73%	-106.07%	-76.17%	7/29/2025 (Estimated)
ESPR Esperion Therapeutics	-$209.25M	-$0.80	N/A	N/A	N/A	-29.37%	N/A	-10.77%	8/11/2025 (Estimated)
MDWD MediWound	-$6.72M	-$2.09	N/A	N/A	N/A	-142.29%	-82.17%	-33.67%	8/13/2025 (Estimated)

Latest ATNM, ESPR, DBVT, and MDWD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	MDWD MediWound	-$0.65	-$0.07	+$0.58	-$0.07	$5.20 million	$3.96 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million
4/11/2025	Q4 2024	DBVT DBV Technologies	N/A	-$1.10	N/A	-$1.10	N/A	$0.51 million
3/19/2025	Q4 2024	MDWD MediWound	-$0.59	-$0.36	+$0.23	-$0.36	$5.79 million	$5.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
DBVT DBV Technologies	N/A	2.22	2.22
ESPR Esperion Therapeutics	N/A	1.85	1.37
MDWD MediWound	N/A	2.11	1.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNM Actinium Pharmaceuticals	27.50%
DBVT DBV Technologies	71.74%
ESPR Esperion Therapeutics	47.39%
MDWD MediWound	46.83%

Insider Ownership

Company	Insider Ownership
ATNM Actinium Pharmaceuticals	6.00%
DBVT DBV Technologies	1.44%
ESPR Esperion Therapeutics	1.70%
MDWD MediWound	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNM Actinium Pharmaceuticals	30	31.20 million	29.32 million	Optionable
DBVT DBV Technologies	80	27.39 million	20.18 million	Optionable
ESPR Esperion Therapeutics	200	198.20 million	195.07 million	Optionable
MDWD MediWound	80	10.81 million	9.79 million	Optionable

ATNM, ESPR, DBVT, and MDWD Headlines

Recent News About These Companies

Brokerages Set MediWound Ltd. (NASDAQ:MDWD) Target Price at $31.25

June 5, 2025 | americanbankingnews.com

MediWound Ltd. (NASDAQ:MDWD) Shares Acquired by Silverberg Bernstein Capital Management LLC

June 3, 2025 | marketbeat.com

Companies Like MediWound (NASDAQ:MDWD) Are In A Position To Invest In Growth

June 2, 2025 | finance.yahoo.com

MediWound Ltd. (NASDAQ:MDWD) Given Average Rating of "Buy" by Analysts

June 2, 2025 | marketbeat.com

MediWound (NASDAQ:MDWD) Coverage Initiated at Oppenheimer

June 2, 2025 | marketbeat.com

What is HC Wainwright's Forecast for MediWound Q2 Earnings?

May 27, 2025 | marketbeat.com

Northern Trust Corp Has $2.58 Million Holdings in MediWound Ltd. (NASDAQ:MDWD)

May 26, 2025 | marketbeat.com

HC Wainwright Forecasts Strong Price Appreciation for MediWound (NASDAQ:MDWD) Stock

May 24, 2025 | marketbeat.com

MediWound (NASDAQ:MDWD) Stock Crosses Above Fifty Day Moving Average - What's Next?

May 24, 2025 | marketbeat.com

MediWound (NASDAQ:MDWD) Releases Earnings Results, Beats Estimates By $0.58 EPS

May 23, 2025 | marketbeat.com

MediWound’s Q1 2025: Strategic Progress Amid Financial Challenges

May 22, 2025 | tipranks.com

MediWound (MDWD) Q1 2025 Earnings Call Transcript

May 21, 2025 | msn.com

MediWound Ltd. (MDWD) Q1 2025 Earnings Call Transcript

May 21, 2025 | seekingalpha.com

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

May 21, 2025 | zacks.com

MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 21, 2025 | globenewswire.com

MediWound Q1 2025 Earnings Preview

May 20, 2025 | msn.com

MediWound Ltd.: Undervalued High-Growth Potential

May 16, 2025 | seekingalpha.com

MediWound (MDWD) to Release Earnings on Wednesday

May 16, 2025 | marketbeat.com

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

May 13, 2025 | globenewswire.com

MediWound to Report First Quarter 2025 Financial Results

May 5, 2025 | globenewswire.com

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

April 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM, ESPR, DBVT, and MDWD Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

$1.49 -0.10 (-6.29%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.49 0.00 (0.00%)

As of 06/13/2025 07:08 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

DBV Technologies NASDAQ:DBVT

$8.96 -0.74 (-7.59%)

As of 06/13/2025 04:00 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Esperion Therapeutics NASDAQ:ESPR

$1.17 -0.03 (-2.50%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.19 +0.02 (+1.62%)

As of 06/13/2025 07:56 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

MediWound NASDAQ:MDWD

$20.42 +0.07 (+0.34%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$20.45 +0.03 (+0.15%)

As of 06/13/2025 07:48 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time